Published on March 11, 2008
Slide1: Presented by Terry Blaschke, M.D. at the meeting of the Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Slide4: Computers and Biomedical Research 1972;5:441-59 Ann Intern Med 1975;82:619-27: Ann Intern Med 1975;82:619-27 Slide6: Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data. Sheiner LB, Beal SL. Individual pharmacokinetic par parameters quantify the pharmacokinetics of an individual, while population pharmacokinetic parameters quantify population mean kinetics, interindividual variability, and residual intraindividual variability plus measurement error. Individual pharmacokinetics are estimated by fitting individual data to a pharmacokinetic model. Population pharmacokinetic parameters are estimated either by fitting all individual's data together as though there was no individual kinetic differences (the naive pooled data approach), or by fitting each individual's data separately, and then combining the individual parameter estimates (the two-stage approach). A third approach, NONMEM, takes a middle course between these, and avoids shortcomings of each of them…This performance is exactly what is expected from theoretical considerations and provides empirical support for the use of NONMEM when estimating population pharmacokinetics from routine type patient data. J Pharmacokinet Biopharm 1980;8:553-71. Slide7: Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J. We propose a model of drug pharmacodynamic response that when integrated with a pharmacokinetic model allows characterization of the temporal aspects of pharmacodynamics as well as the time-independent sensitivity component. The total model can accommodate extremes of effect. It allows fitting of simultaneous plasma concentration (Cp) and effect data from the initial distribution phase of drug administration, or from any non-equilibrium phase. The model postulates a hypothetical effect compartment, the dynamics of which are adjusted to reflect the temporal dynamics of drug effect. Clin Pharmacol Ther 1979;25:358-71 Three Compartment Model plus an “Effect Site”: Three Compartment Model plus an “Effect Site” Slide9: Clinical Pharmacokinetics 1981;6:429-53 Slide10: Clin Pharmacol Ther 1989;46:63-77 Slide11: Drug Regimens EXPOSURE INPUT PROFILE Drug Effects (EFFICACY/TOXICITY) Patient Characteristics age kidney function severity of illness Benefit:Risk Response Surface (Courtesy of Lewis Sheiner) * * RCT Slide13: Br J Clin Pharmacol, 2000;54:203–11 Slide16: Annu Rev Pharmacol Toxicol 2000;40:67-95 FDA SERVICE & ADVISORY BOARDS -: FDA SERVICE & ADVISORY BOARDS - 1987- Expert Consultant to the FDA; Center FOR Drug Evaluation and Research (formerly Center for Drugs and Biologics), Rockville, MD 1991-94 Member, Antiviral Drugs Advisory Committee, CDER, FDA, Rockville, MD 1997 Member, Expert panel: Guidance on Population PK/PD, CDER, FDA, Rockville, MD. 1998- Member, Expert Panel: Individual and Population Bioequivalence, CDER, FDA, Rockville, MD 1999- Member, Expert Panel: Exposure-Response Guidance, CDER, FDA, Rockville, MD 2002- Member, Clinical Pharmacology Subcommittee VISITING FACULTY SUPERVISED:: VISITING FACULTY SUPERVISED: Brian Whiting, MD Adrian Dunne, PhD (with SL Beal) Robert Laplanche, PhD Margaret Lynn McFayden, PhD Pascal Girard, PhD Margareta Hammarlund-Udenaes, PhD Xiaojaian Zhou, PhD Jeffrey Koup, PhD POST DOCTORAL SCHOLARS SUPERVISED:: POST DOCTORAL SCHOLARS SUPERVISED: Carl Peck, MD Diana Nicoll, MD, PhD Hillel Halkin, MD Samuel Vozeh, MD Renato Galeazzi, MD Donald Stanski, MD Peter Ravenscroft, MD David Wicker, MD Nestor Sanchez, MD Thaddeus Grasela, PharmD Eliane Fuseau, PhD Johan Gabrielson, PhD Nicholas Holford, MSc, MB, CHB Jashvant Unadkat, PhD Lawrence Wheeler, MD, PhD Stanley Perkins, MD Herve Porchet, MD Nancy Sambol, PharmD Ferenc Bartha Davide Verotta, PhD Yukiya Hashimoto, PhD Beny Mozes, MD Shi Jun, MD Ruediger Port, MD Dominik Uehlinger, MD Leslie Lenert, MD (Stanford) Kazumasa Aizawa, PhD Inaki Fernandez-Toconiz, PhD Mats Karlsson, PhD Karen Fattinger-Bachmann, MD Jacob Mandema, PhD Janet Wade, PhD (with N. Sambol) Kyungsoo Park, PhD Jean-Michel Gries, PhD Atsunori Kaibara, PhD Saraswati Kinkare, PhD Christine Veyrat, PhD Eugene Cox, PhD Yoshitaka Yano, PhD Ikuko Yano, PhD (with S. Beal) Niclas Jonsson, PhD Jianfeng Lu, PhD Marc Pfister, MD Line Labbe, PhD Dolors Soy, PhD Micha Levy, PhD
Terry Blaschke, M.D. at the meeting of the Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science ...
11/5/2004. Presented by Terry Blaschke, M.D. at the meeting of the Clinical Pharmacology Subcommittee of the Advisory Committee for ...
Information about Yoshitaka Yano from Hawaii, California and Japan. ... 2004 4079S2 01 Blaschke Sheiner Tribute Ppt Presentation www.authorstream.com
Looking for Lynn Mcfayden ? PeekYou's people search has 5 people named Lynn Mcfayden and you can find info, photos, links, family members and more
Pharmacokinetic Principles - University of Sydney. Pharmacodynamics … Agonists and ... Northern Clinical School Clinical Pharmacology Lectures... http ...